Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension
- PMID: 8282334
- DOI: 10.1161/01.hyp.23.1.83
Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension
Abstract
Seventeen male untreated mild essential hypertensive patients aged 41 +/- 2 years agreed to participate in a double-blind randomized trial to test the effects of antihypertensive treatment on the structure and function of subcutaneous resistance arteries. Patients were treated with either 50 to 100 mg/d atenolol or 2.5 to 5 mg/d cilazapril. Blood pressure before treatment was 148 +/- 6/99 +/- 1 and 147 +/- 2/99 +/- 1 mm Hg, respectively. At 1 year of treatment blood pressure was 131 +/- 4/85 +/- 2 and 132 +/- 2/87 +/- 1 mm Hg, respectively. Resistance arteries (200 to 400 microns lumen diameter) dissected from subcutaneous gluteal biopsies obtained before treatment and at 1 year showed that the media-lumen ratio of arteries from patients treated with cilazapril was reduced to 6.31 +/- 0.21% from 7.54 +/- 0.31% before treatment (P < .05), still slightly but significantly larger (P < .05) than the media-lumen ratio of resistance arteries of normotensive control subjects (5.15 +/- 0.30%). In contrast, in arteries from patients treated with atenolol there was no significant change with treatment (7.97 +/- 0.60% before and 8.07 +/- 0.45% after 1 year of treatment). Active wall tension responses to endothelin-1 were blunted in hypertensive patients and normalized in the cilazapril-treated patients. Depressed active media stress responses to norepinephrine, arginine vasopressin, and endothelin-1 were accordingly normalized in the patients receiving cilazapril as the media width became thinner but were unchanged in those taking atenolol.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
[Prospective study of the effects of an angiotensin converting enzyme inhibitor and a beta blockader on the structure and function of resistant arteries in mild essential hypertension].Arch Mal Coeur Vaiss. 1994 Aug;87(8):979-81. Arch Mal Coeur Vaiss. 1994. PMID: 7755476 Clinical Trial. French.
-
Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.J Cardiovasc Pharmacol. 1994;24 Suppl 3:S51-6. J Cardiovasc Pharmacol. 1994. PMID: 7700067 Review.
-
Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor.J Cardiovasc Pharmacol. 1996;27 Suppl 2:S13-8. doi: 10.1097/00005344-199600002-00004. J Cardiovasc Pharmacol. 1996. PMID: 8723394 Clinical Trial.
-
Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker.Am J Hypertens. 1995 Mar;8(3):229-36. doi: 10.1016/0895-7061(95)96211-2. Am J Hypertens. 1995. PMID: 7794571 Clinical Trial.
-
Remodeling of resistance arteries in human hypertension: effects of cilazapril, an angiotensin-I-converting enzyme inhibitor.Cardiology. 1995;86 Suppl 1:16-22. doi: 10.1159/000176941. Cardiology. 1995. PMID: 7614501 Review.
Cited by
-
Vascular effects of antihypertensive drug therapy.Curr Hypertens Rep. 2010 Aug;12(4):226-32. doi: 10.1007/s11906-010-0117-3. Curr Hypertens Rep. 2010. PMID: 20514556 Review.
-
Vascular Smooth Muscle Remodeling in Conductive and Resistance Arteries in Hypertension.Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):1969-1985. doi: 10.1161/ATVBAHA.118.311229. Arterioscler Thromb Vasc Biol. 2018. PMID: 30354262 Free PMC article. Review.
-
Manidipine-delapril combination in the management of hypertension.Vasc Health Risk Manag. 2007;3(3):255-63. Vasc Health Risk Manag. 2007. PMID: 17703633 Free PMC article. Review.
-
Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature.J Cell Mol Med. 2010 May;14(5):1018-29. doi: 10.1111/j.1582-4934.2010.01056.x. Epub 2010 Mar 19. J Cell Mol Med. 2010. PMID: 20345850 Free PMC article. Review.
-
The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.Endocrinology. 2008 Oct;149(10):4780-93. doi: 10.1210/en.2008-0318. Epub 2008 Jun 5. Endocrinology. 2008. PMID: 18535098 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical